Lilly (Eli) (LLY): financials, SEC filings and peers
Lilly (Eli) (LLY) is a pharmaceuticals company in the Health Care sector of the S&P 500, headquartered in Indianapolis, Indiana.
It was founded in 1876 and joined the S&P 500 on December 31, 1970.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Pharmaceutical Preparations”.
Lilly (Eli) at a glance
- Revenue (12 months)
- $86.5B
- Revenue growth
- +45.5%
- Operating margin
- 40.2%
- Net income (12 months)
- $27.6B
- Free cash flow (12 months)
- —
- Cash
- $4.9B
- Debt
- $49.5B
- Diluted EPS (12 months)
- $30.81
Twelve months to September 30, 2026, from the 10-Q filed October 29, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Lilly (Eli) reported revenue of $86.5 billion, up a strong 45.5% from $59.4 billion a year earlier.
Its operating margin was 40.2%: for every $100 of sales, about $40 was left as operating profit.
Net income was $27.6 billion (31.9% of revenue), 49.8% higher than a year earlier.
At the end of the period it held $4.9 billion in cash and $49.5 billion in debt, a net debt position of $44.6 billion.
Five-year trend
- Revenue went from $24.5 billion in fiscal 2020 to $65.2 billion in fiscal 2025, about 21.6% a year.
- Revenue has grown for 5 fiscal years in a row.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Revenue growth | 15.4% | 0.8% | 19.6% | 32.0% | 44.7% |
| Operating margin | — | — | — | — | — |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Free cash flow | — | — | — | — | — |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
Fiscal years as reported in Lilly (Eli)’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed October 29, 2026 — quarterly report
- 8-K filed October 29, 2026 — Earnings results
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 5, 2026 — Earnings results
- 8-K filed May 20, 2026 — Other event
- 8-K filed May 7, 2026 — Shareholder vote results
- 10-Q filed April 30, 2026 — quarterly report
- 8-K filed April 30, 2026 — Earnings results
Companies like Lilly (Eli)
Other S&P 500 companies in Pharmaceuticals:
- BMYBristol Myers SquibbNew York City, New York
- JNJJohnson & JohnsonNew Brunswick, New Jersey
- MRKMerck & Co.Kenilworth, New Jersey
- PFEPfizerNew York City, New York
- VTRSViatrisPittsburgh, Pennsylvania
- ZTSZoetisParsippany, New Jersey
More from Health Care
Questions about Lilly (Eli)
Is Lilly (Eli)'s revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $86.5 billion, up 45.5% from a year earlier, according to its SEC filings.
Is Lilly (Eli) profitable?
Yes. It earned $27.6 billion in net income over the twelve months to September 30, 2026, a net margin of 31.9%.
Does Lilly (Eli) have more cash or more debt?
At September 30, 2026 it had $4.9 billion in cash and $49.5 billion in debt, so more debt than cash.
When did Lilly (Eli) last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on October 29, 2026.
Which companies are similar to Lilly (Eli)?
In the S&P 500, Lilly (Eli) is grouped in Pharmaceuticals within the Health Care sector. Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Merck & Co. (MRK), Pfizer (PFE), Viatris (VTRS) are in the same group.
Understand the numbers
Source: Lilly (Eli)’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.